Comparison Between One Week Versus Two Weeks Vonoprazan and High Dose Amoxicillin Dual Therapy for Eradication of Helicobacter Pylori in Egyptian Patients
Abo Elkasem, A., Ghoniem, H., Abdel Fattah, A., Fahmy, A. (2025). Comparison Between One Week Versus Two Weeks Vonoprazan and High Dose Amoxicillin Dual Therapy for Eradication of Helicobacter Pylori in Egyptian Patients. EKB Journal Management System, 6(4), 7-16. doi: 10.21608/ejmr.2025.390978.1839
Asmaa Hussien Abo Elkasem; Hossam Mahmoud Sabry Ghoniem; Ali Mohammed Abdel Fattah; Al Zahraa Mohammed Fahmy. "Comparison Between One Week Versus Two Weeks Vonoprazan and High Dose Amoxicillin Dual Therapy for Eradication of Helicobacter Pylori in Egyptian Patients". EKB Journal Management System, 6, 4, 2025, 7-16. doi: 10.21608/ejmr.2025.390978.1839
Abo Elkasem, A., Ghoniem, H., Abdel Fattah, A., Fahmy, A. (2025). 'Comparison Between One Week Versus Two Weeks Vonoprazan and High Dose Amoxicillin Dual Therapy for Eradication of Helicobacter Pylori in Egyptian Patients', EKB Journal Management System, 6(4), pp. 7-16. doi: 10.21608/ejmr.2025.390978.1839
Abo Elkasem, A., Ghoniem, H., Abdel Fattah, A., Fahmy, A. Comparison Between One Week Versus Two Weeks Vonoprazan and High Dose Amoxicillin Dual Therapy for Eradication of Helicobacter Pylori in Egyptian Patients. EKB Journal Management System, 2025; 6(4): 7-16. doi: 10.21608/ejmr.2025.390978.1839

Comparison Between One Week Versus Two Weeks Vonoprazan and High Dose Amoxicillin Dual Therapy for Eradication of Helicobacter Pylori in Egyptian Patients

Egyptian Journal of Medical Research
Volume 6, Issue 4, October 2025, Pages 7-16    PDF (609.27 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2025.390978.1839
Authors
Asmaa Hussien Abo Elkasem* ; Hossam Mahmoud Sabry Ghoniem; Ali Mohammed Abdel Fattah; Al Zahraa Mohammed Fahmy
Tropical Medicine Department, Faculty of Medicine Bani-Suef University
Abstract
Background: Helicobacter pylori infection is highly prevalent and associated with several gastrointestinal and extra-gastrointestinal diseases. Traditional eradication regimens face increasing antibiotic resistance, particularly to clarithromycin. Vonoprazan, a novel potassium-competitive acid blocker, offers promising acid suppression with potential to enhance eradication when combined with amoxicillin. This study aimed to compare the efficacy and safety of a 1-week versus 2-week vonoprazan and high-dose amoxicillin dual therapy in Egyptian patients with H. pylori infection. Methods: This cohort comparative observational study was conducted at Bani-Suef University Hospital over six months, enrolling 60 adult patients with confirmed H. pylori infection. Patients were randomized into two groups: Group A received vonoprazan 20 mg twice daily and amoxicillin 1 g three times daily for 14 days, while Group B received the same regimen for 7 days. Eradication was confirmed by stool antigen testing two weeks’ post-therapy. Adverse effects and patient compliance were monitored. Results: The eradication rate was 80% in Group A and 76.7% in Group B, with no statistically significant difference (p > 0.05). Reported side effects were mild and similar in both groups (20% vs. 23.3%, p > 0.05), with no severe adverse events. Multivariate analysis revealed no significant predictors of treatment response. Conclusion: One-week and two-week dual therapies with vonoprazan and high-dose amoxicillin yielded comparable eradication rates and tolerability in Egyptian patients. Shorter therapy may be a viable, cost-effective alternative in clinical practice.
Keywords
Helicobacter pylori; Vonoprazan; amoxicillin; dual therapy; eradication
References

  1. Park, J. Y., Greenberg, E. R., Parsonnet, J., et al. (2014). Summary of IARC working group meeting on Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC Work Group Report, 8, 1-4.
  2. Malfertheiner, P., Megraud, F., O'Morain, C. A., et al. (2012). Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut, 61(5), 646-664.
  3. Leja, M., Grinberga‐Derica, I., Bilgilier, C., et al. (2019). Epidemiology of Helicobacter pylori infection. Helicobacter, 24, e12635.
  4. Graham, D. Y., & Laine, L. (2016). The Toronto Helicobacter pylori consensus in context. Gastroenterology, 151(1), 9-12.
  5. Zhang, Y., Meng, F., Jin, J., et al. (2021). Ninety-four thousand-case retrospective study on antibacterial drug resistance of Helicobacter pylori. World Journal of Clinical Cases, 9(35), 10838.
  6. Chey, W. D., Mégraud, F., Laine, L., et al. (2022). Vonoprazan triple and dual therapy for Helicobacter pylori infection in the United States and Europe: randomized clinical trial. Gastroenterology, 163(3), 608-619.
  7. Kusano, C., Gotoda, T., Suzuki, S., et al. (2018). Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. Journal of Gastroenterology, 53, 718-724.
  8. Yang, F., Yu, B., Qin, L., et al. (2023). A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori. Medicine, 102(41), e35610.
  9. Sue, S., Kondo, M., Sato, T., et al. (2023). Vonoprazan and high‐dose amoxicillin dual therapy for Helicobacter pylori first‐line eradication: a single‐arm, interventional study. JGH Open, 7(1), 55-60.
  10. Şeyda, T., Derya, Ç., Füsun, A., et al. (2007). The relationship of Helicobacter pylori positivity with age, sex, and ABO/Rhesus blood groups in patients with gastrointestinal complaints in Turkey. Helicobacter, 12(3), 244-250.
  11. Furuta, T., Yamade, M., Kagami, T., et al. (2020). Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan, amoxicillin and clarithromycin for eradication of Helicobacter pylori. Digestion, 101(6), 743-751.
  12. Lyu, Q. J., Pu, Q. H., Zhong, X. F., et al. (2019). Efficacy and safety of vonoprazan‐based versus proton pump inhibitor‐based triple therapy for Helicobacter pylori eradication: a meta‐analysis of randomized clinical trials. BioMed Research International, 2019(1), 9781212.
  13. Peña-Galo, E., Gotor, J., Harb, Y., et al. (2021). Socioeconomic and demographic factors associated with failure in Helicobacter pylori eradication using the standard triple therapy. Gastroenterology and Hepatology From Bed to Bench, 14(1), 53.
  14. Choi, Y. J., Lee, Y. C., Kim, J. M., et al. (2022). Triple therapy-based on tegoprazan, a new potassium-competitive acid blocker, for first-line treatment of Helicobacter pylori infection: a randomized, double-blind, phase III, clinical trial. Gut and liver, 16(4), 535.
 

Statistics
Article View: 58
PDF Download: 36